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Summary
Hepatitis C virus (HCV) chronic infection can be associated with extrahepatic manifestations such as mixed cryoglobulinaemia and lymphoproliferative disorders that are endowed with increased rates of morbidity and all-cause mortality. In this study, we used flow cytometry to evaluate the effect of interferon-free antiviral treatment on peripheral blood lymphocytes in HCV-infected patients with or without associated lymphoproliferative disorders. Flow cytometry analysis of peripheral blood lymphocytes was performed at baseline and at the end of treatment. In HCV-infected patients with lymphoproliferative disorders, we evaluated immunoglobulin (Ig) light chain κ/λ ratio variations as a measure of monoclonal B-cell response to antiviral therapy. Healthy volunteers were enrolled as controls. A total of 29 patients were included, nine with and 20 without lymphoproliferative disorders. Sustained virological response was achieved in 29 of 29 patients. We observed a significant reduction in the B-cell compartment (39% global reduction) in eight of nine HCV-infected patients with lymphoproliferative disorders after viral clearance. We recognized the same trend, even if less pronounced, in HCV-infected patients without lymphoproliferative disorders (9% global reduction). Among HCV-infected patients with lymphoproliferative disorders, three showed an improvement/normalization of the immunoglobulin light chain ratio, whereas in the remaining six patients monoclonal B cells persisted to be clonally restricted even 1 year after the end of treatment. Our data show that DAAs treatment can be effective in reducing the frequency of pathological B cells in the peripheral blood of HCV-infected patients affected by HCV-associated lymphoproliferative disorders; however, monoclonal populations can persist after viral eradication.
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| INTRODUCTION
HCV infection is associated with both hepatic and extrahepatic manifestations. Among the latter, LPDs are correlated with HCV lymphotropism and oncogenic potential. Epidemiological studies have confirmed the association between HCV chronic infection and a broad spectrum of LPDs such as mixed cryoglobulinaemia (MC) and different B-cell non-Hodgkin's lymphoma (B-NHL) subtypes.
2-6
However, the understanding of the molecular mechanisms linking HCV active infection to lymphoma development is still limited.
Several reports documented the ability of HCV to induce B lymphocytes proliferation by antigen stimulation and/or by interaction of the E2 viral envelope protein with the CD19/CD21/CD81 complex, 7, 8 but a more recent study failed to demonstrate the presence of HCVspecific B-cell receptors on the surface of lymphoma cells derived from B-NHL associated with HCV infection. However, the restricted usage of immunoglobulin VH-169 in lymphoma cells supports antigendriven proliferation and clonal selection as a causative mechanism for HCV-associated B-NHL development. 9 Moreover, the high prevalence of monoclonal lymphocytosis in HCV-infected patients supports the notion that neoplastic transformation could be caused by chronic antigenic stimulation and clonal selection.
10,11
Yet, the response of B-NHLs to antiviral treatment provides the strongest evidence for a potential causative role of HCV in lymphomagenesis. This was initially observed in nine patients with splenic lymphoma who underwent interferon (IFN)-α-based antiviral treatment.
All patients who achieved sustained virological response (SVR) obtained lymphoma regression. Importantly, a correlation was observed between haematologic and virological response.
12 Later reports confirmed that IFN-α-based antiviral treatments can be efficacious for treating HCV-associated lymphomas. [13] [14] [15] [16] [17] [18] [19] As IFN-free antiviral regimens became widely available, some case reports and data on a larger series of HCV patients affected by B-NHL treated with the new antivirals have been published, confirming that viral clearance can also be effective on the associated LPDs.
20-24
However, all these interventional studies evaluated the haematologic response mainly by clinical criteria, whereas little is known at the cellular and molecular level.
In this study, we have investigated by flow cytometry the effect of HCV eradication following IFN-free antiviral therapy on peripheral lymphocytes of patients with and without HCV-associated LPDs. as noninvasive method to evaluate liver fibrosis.
| PATIENTS AND METHODS

| Patients
The study was conducted according to the Declaration of Helsinki.
All patients gave written consent for data collection. The study was approved by the Padua University Hospital ethical committee (protocol number: 3103/A014).
| Immunophenotyping
All blood samples were EDTA-anticoagulated and analysed on the same day of the collection to avoid cellular death. Sample preparation and analysis were performed according to the CLSI guidelines.
26,27
Total lymphocyte, neutrophil and platelet counts were measured with an XE-5000 haematology analyzer (Sysmex). The absolute frequencies of cell subsets were calculated on the basis of the relative frequencies on total lymphocytes.
Samples were probed before the beginning and at least 1 month after the end of treatment to avoid direct effects of the therapy. 
| Statistical analysis
Statistical analyses were performed using Prism 5 (GraphPad Software, San Diego, CA, USA). Nonparametric statistics were used because many of the data were not normally distributed. Tests used were the MannWhitney U test for unpaired comparisons and the Wilcoxon signedrank test for paired comparisons. Two-tailed P values were calculated for all tests. An α of 0.05 was defined as the cut-off for significance. Mean liver stiffness after therapy was 16 kPa (range 4-38) with no statistically significant difference when compared to pre-antiviral therapy evaluation (P=.7).
| RESULTS
| Characteristics of the study population
Twenty healthy volunteers were included as controls. Cohort characteristics are summarized in Tables 1-3 .
| Flow cytometry analysis
| HCV+/LPD− patients
All HCV+/LPD− patients presented with no evidence for the presence of monoclonal lymphocyte populations in the peripheral blood before and after antiviral treatment.
Patients total lymphocyte count did not significantly differ from that of a control group and was not affected by HCV eradication (Figure 1 ).
Regarding CD3+ T cells, no differences were found in terms of frequency and absolute count between patients and controls (P=.7 and
P=.4, respectively).
CD3+ cell relative frequency increased significantly in HCVinfected patients after treatment. Distribution of helper and cytotoxic T cells is reported in Fig. S1 . (Figures 2 and 3) The variance of CD19+ B cells was also higher in patients both before (P=.0003) and after (P=.0009) treatment when compared to controls.
In HCV-infected patients, the serum γ globulin concentration significantly decreased after the end of therapy (mean 14.69 g/L, SD 4.5 vs mean 17.21 g/L, SD 5, P=.001), whereas total proteins were unaffected.
CD16+ CD56+ double-positive NK cells were consistently reduced both before and after treatment in HCV-infected patients.
| HCV+/LPD+ patients
All HCV+/LPD+ patients showed the presence of monoclonal B-cell populations in the peripheral blood as revealed by surface immunoglobulin light chain expression unbalance (abnormal κ/λ ratio, normal reference range 1-3) with or without other immunophenotypic aberrancies (Table 3) .
None of these patients presented with lymphocytosis, and the total lymphocyte count did not differ from that of the control group before treatment (P=.3). Nonetheless, total lymphocyte count was significantly reduced after DAAs treatment in HCV-infected patients In HCV+/LPD+ patients CD19+ B cells ranged from 10% to 44%
and from 4% to 32% before and after treatment, respectively, with (Fig. S3) .
F I G U R E 2 Total lymphocyte count and subset distribution, serum protein and gamma globulin concentration before and after DAAs treatment in nine patients affected by HCV-associated LPDs. (A) Total lymphocyte count of HCV/LPD patients did not differ from that of healthy controls but was significantly lower after antiviral treatment than in the pretreatment group.
(B) Peripheral blood T-cell (CD3+, reference range 57%-81%) B-cell (CD19+, reference range 7%-21%) and NK-cell (CD16+CD56+, reference range 7%-27%) relative frequencies were determined by flow cytometry and expressed as percentages of the total gated lymphocytes. Note the broader range of CD3+ and CD19+ cells in HCV/LPD patients compared to healthy controls. (C) CD3+ cells were lower in patients than in controls and increased as relative, but not absolute frequency after treatment. CD19+ cells were increased in patients before treatment and strongly reduced after the therapy. CD16+CD56+ NK cells were consistently reduced both before and after treatment in HCV-infected patients. (D) Serum protein electrophoresis showed that gamma globulin concentration was significantly reduced after treatment, while total protein concentration was not changed in HCV-infected patients. 
| Monoclonal B-cell populations
To study the effect of DAAs on monoclonal B-cell populations, immunoglobulin light chain κ and λ surface expression were evaluated before and after the treatment as a marker for clonality ( Figure 3 ).
By combining B-cell count with κ/λ expression data, three different response groups were identified:
1. in three patients (two MBL and one MCS patients), both pathological B cells reduction and κ/λ ratio improvement/normalization were observed.
2. in five patients (one MBL and four B-NHL patients), despite a reduction in the B-cell compartment, no improvement in κ/λ ratio was found even after 1 year from the end of treatment.
in one patient (CD5+ B-NHL), an increased pathological CD5+
B-cell count with no improvement in the κ/λ ratio at 1 year after the end of treatment was observed.
| DISCUSSION
HCV-related B-NHL response to antiviral therapy has been extensively documented. [12] [13] [14] [15] [16] [17] [18] [19] Haematologic response to antiviral treatment was usually defined mainly by clinical parameters. 29, 30 In our series, we observed Indeed, as proposed by Zignego et al., 34 the persistence of the abovementioned stigmata can be, in some cases, related to short follow-ups as well as to the overcoming of pathogenetic no-return points.
Overt diseases, probably because of further unfavourable oncogenic events, acquire autonomous growth ability and consequently partial or complete resistance to antiviral treatment, as suggested also by our experience.
Our study has some limitations. First, the follow-up period is relatively short. Certainly, a longer follow-up is needed to verify the longterm effects of viral eradication on monoclonal B-cell populations.
Second, the sample size, a wider sample and other centre experiences are indispensable to confirm these preliminary findings. Finally, no molecular evaluation underpinning the association between HCV status and lymphocyte populations was carried out.
In conclusion, HCV eradication following DAAs treatments is associated with a rapid and consistent reduction in circulating pathological B cells in the majority of patients. However, monoclonal B-cell populations can persist after viral eradication. Further studies are needed to better understand the molecular relationship between HCV and B-cell transformation.
